当前位置:首页 - 行情中心 - 康泰生物(300601) - 财务分析 - 现金流量表

康泰生物

(300601)

  

流通市值:153.97亿  总市值:190.99亿
流通股本:9.00亿   总股本:11.17亿

现金流量表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金1,981,526,371.411,227,569,112.81544,167,223.262,796,306,483.64
  收到其他与经营活动有关的现金73,091,000.5755,930,211.5137,579,608.67137,312,136.94
  经营活动现金流入小计2,054,617,371.981,283,499,324.32581,746,831.932,933,618,620.58
  购买商品、接受劳务支付的现金263,717,833.14173,472,752.5891,121,906.96370,479,559.48
  支付给职工以及为职工支付的现金383,721,957.42267,864,630.99139,614,676533,609,185.01
  支付的各项税费88,246,884.1965,085,077.0531,820,790.28122,503,462.44
  支付其他与经营活动有关的现金956,467,397.5701,480,111.3365,492,876.671,303,776,708.82
  经营活动现金流出小计1,692,154,072.251,207,902,571.92628,050,249.912,330,368,915.75
  经营活动产生的现金流量净额362,463,299.7375,596,752.4-46,303,417.98603,249,704.83
二、投资活动产生的现金流量:
  收回投资收到的现金2,091,800,000834,000,00060,000,000790,000,000
  取得投资收益收到的现金152,249,834.4533,674,638.3688,602.7456,742,843.34
  处置固定资产、无形资产和其他长期资产收回的现金净额53,22546,8001,22016,151,556.46
  投资活动现金流入小计2,244,103,059.45867,721,438.3660,089,822.74862,894,399.8
  购建固定资产、无形资产和其他长期资产支付的现金203,515,398.79159,983,023.59125,315,698.65472,181,999.18
  投资支付的现金1,366,800,001710,000,001-947,400,000
  投资活动现金流出小计1,570,315,399.79869,983,024.59125,315,698.651,419,581,999.18
  投资活动产生的现金流量净额673,787,659.66-2,261,586.23-65,225,875.91-556,687,599.38
三、筹资活动产生的现金流量:
  取得借款收到的现金39,900,00039,900,00025,500,000212,621,632.83
  收到其他与筹资活动有关的现金11,765,606.1184,357.7884,357.7811,605,349.42
  筹资活动现金流入小计51,665,606.1139,984,357.7825,584,357.78224,226,982.25
  偿还债务支付的现金248,591,749.54223,091,749.54122,991,749.54743,152,554.23
  分配股利、利润或偿付利息支付的现金131,552,215.86101,464,255.51692,363.7256,620,086.84
  支付其他与筹资活动有关的现金1,789,654.941,463,146.63842,025.0625,212,258.95
  筹资活动现金流出小计381,933,620.34326,019,151.68124,526,138.31,024,984,900.02
  筹资活动产生的现金流量净额-330,268,014.23-286,034,793.9-98,941,780.52-800,757,917.77
四、汇率变动对现金及现金等价物的影响-380,193.69-205,643.66-62,987.62-60,732.33
五、现金及现金等价物净增加额705,602,751.47-212,905,271.39-210,534,062.03-754,256,544.65
  加:期初现金及现金等价物余额416,069,254.45416,069,254.45416,069,254.451,170,325,799.1
  期末现金及现金等价物余额1,121,672,005.92203,163,983.06205,535,192.42416,069,254.45
补充资料:
  净利润-37,600,910.41-201,553,722.8
  资产减值准备-93,665,145.75-231,519,516.32
  固定资产和投资性房地产折旧-177,103,275.73-281,785,121.33
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-177,103,275.73-281,785,121.33
  无形资产摊销-22,193,837.92-35,453,043.89
  长期待摊费用摊销-22,497,376.09-36,217,043.5
  处置固定资产、无形资产和其他长期资产的损失-365,901.81-8,415,471.25
  固定资产报废损失-1,929,965.86-563,629.84
  公允价值变动损失--58,300--1,380,868.09
  财务费用-15,712,158.75-34,104,963.89
  投资损失--99,250.45--465,020.57
  递延所得税--37,722,832.42--57,932,839.87
  其中:递延所得税资产减少--35,306,967.37--65,715,398.85
    递延所得税负债增加--2,415,865.05-7,782,558.98
  存货的减少-6,306,540.69--79,029,008.63
  经营性应收项目的减少--148,527,495.63--20,261,585.89
  经营性应付项目的增加--143,174,781.72--183,761,170.95
  其他---86,990,899.08
  现金的期末余额-203,163,983.06-416,069,254.45
  减:现金的期初余额-416,069,254.45-1,170,325,799.1
  现金及现金等价物的净增加额--212,905,271.39--754,256,544.65
公告日期2025-10-282025-08-222025-04-212025-04-21
审计意见(境内)标准无保留意见
TOP↑